Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01015833 |
Recruitment Status
:
Active, not recruiting
First Posted
: November 18, 2009
Last Update Posted
: August 23, 2017
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Advanced Adult Hepatocellular Carcinoma Non-Resectable Hepatocellular Carcinoma Recurrent Hepatocellular Carcinoma Stage III Hepatocellular Carcinoma AJCC v7 Stage IIIA Hepatocellular Carcinoma AJCC v7 Stage IIIB Hepatocellular Carcinoma AJCC v7 Stage IIIC Hepatocellular Carcinoma AJCC v7 Stage IV Hepatocellular Carcinoma AJCC v7 Stage IVA Hepatocellular Carcinoma AJCC v7 Stage IVB Hepatocellular Carcinoma AJCC v7 | Drug: Doxorubicin Hydrochloride Other: Laboratory Biomarker Analysis Other: Pharmacogenomic Study Drug: Sorafenib Tosylate | Phase 3 |
PRIMARY OBJECTIVES:
I. Compare the overall survival (OS) of patients treated with sorafenib (sorafenib tosylate) and doxorubicin (doxorubicin hydrochloride) to that of those treated with sorafenib.
SECONDARY OBJECTIVES:
I. Compare time to progression (TTP) of patients treated with sorafenib and doxorubicin to that of those treated with sorafenib.
II. Compare progression-free-survival (PFS) of patients treated with sorafenib and doxorubicin to that of those treated with sorafenib.
III. Compare tumor response using Response Evaluation Criteria in Solid Tumors (RECIST) criteria of patients treated with sorafenib and doxorubicin to that of those treated with sorafenib.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive doxorubicin hydrochloride intravenously (IV) on day 1 and sorafenib tosylate orally (PO) once daily (QD) or twice daily (BID) on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, patients may continue to receive sorafenib tosylate PO QD or BID in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive sorafenib tosylate PO QD or BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 1 year and then every 6 months for 2 years.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 360 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Investigator) |
Primary Purpose: | Treatment |
Official Title: | Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) |
Actual Study Start Date : | February 15, 2010 |
Actual Primary Completion Date : | May 21, 2015 |
Arm | Intervention/treatment |
---|---|
Experimental: Arm I (doxorubicin hydrochloride, sorafenib tosylate)
Patients receive doxorubicin hydrochloride IV on day 1 and sorafenib tosylate PO QD or BID on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, patients may continue to receive sorafenib tosylate PO QD or BID in the absence of disease progression or unacceptable toxicity.
|
Drug: Doxorubicin Hydrochloride
Given IV
Other: Laboratory Biomarker Analysis
Correlative studies
Other: Pharmacogenomic Study
Correlative studies
Drug: Sorafenib Tosylate
Given PO
|
Experimental: Arm II (sorafenib tosylate)
Patients receive sorafenib tosylate PO QD or BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
|
Other: Laboratory Biomarker Analysis
Correlative studies
Other: Pharmacogenomic Study
Correlative studies
Drug: Sorafenib Tosylate
Given PO
|
- Overall survival [ Time Frame: Up to 3 years ]The confidence bound estimates for futility will also be adjusted according to the Lan-DeMets analogue of the O'Brien-Fleming boundaries.
- Incidence of adverse events, as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 [ Time Frame: Up to 3 years ]Incidence of other adverse events (proteinuria, hypertension, and other common side effects of study drugs) will be assessed.
- Progression free survival [ Time Frame: Up to 3 years ]The stratified log-rank test will be used.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients must have pathologically or cytologically proven hepatocellular carcinoma; known mixed histology (e.g. hepatocellular carcinoma plus cholangiocarcinoma) or fibrolamellar variant is not allowed
- Patients must have locally advanced or metastatic disease; locally advanced disease is defined as disease deemed to be unresectable or non-eligible for transplant without distant metastases
- Lesions must be accurately measurable in at least one dimension (longest diameter to be recorded) as >= 2 cm with conventional techniques or as >= 1 cm with spiral computed tomography (CT) scan
- No prior adjuvant sorafenib or other v-RAF-1 murine leukemia viral oncogene homolog (Raf)/vascular endothelial growth factor (VEGF) inhibitors; other prior adjuvant therapy is allowed if completed > 6 months prior to registration with documented recurrence of hepatocellular carcinoma (HCC)
-
Patients may have been treated with loco regional therapies provided that they either have:
- A target lesion that has not been subjected to local therapy or
-
The target lesion(s) within the field of the local therapy has shown an increase of >= 20% in the size since last treatment
- Such therapy must be completed at least 4 weeks prior to registration; patients that have received palliative radiation therapy to the bone need not wait 4 weeks to begin protocol therapy
-
Prior therapies allowed include the following:
- Bland embolization, radiation, radioactive microspheres, etc
- Chemoembolization using any chemotherapy (except, see below)
- Chemoembolization drug-eluting beads using doxorubicin
- Prior therapy with chemoembolization using doxorubicin in the non drug eluting beads form is NOT allowed
- No prior systemic therapy for metastatic disease
- No prior exposure to systemic doxorubicin administered intravenously
- Antiviral treatment is allowed, however interferon therapy must be stopped at least 4 weeks prior to registration
- Allografts are not allowed: no prior history of any allograft, including but not limited to liver and bone marrow transplants
- Patients must have completed any major surgery >= 4 weeks from registration
- Concomitant treatment with Rifampin or St John's wort is not allowed; patients should discontinue these drugs at least 4 weeks prior to registration
- No known central nervous system (CNS) tumors including brain metastases
- No clinically significant gastrointestinal bleeding events requiring intervention, transfusion, or admission to hospital within 30 days prior to registration
- Patients with a history of hypertension should be well controlled (< 140/90 mmHg) on a regimen of anti-hypertensive therapy
-
Significant history of cardiac disease is not allowed:
- Congestive heart failure > class II New York Heart Association (NYHA)
- Myocardial infarction within 6 months prior to registration
- Serious myocardial dysfunction, defined as scintigraphically (multigated acquisition scan [MUGA], myocardial scintigram) determined absolute left ventricular ejection fraction (LVEF) below 45% or an LVEF on echocardiogram (ECHO) below the normal limit at the individual institution
- No history of bleeding diathesis
- Patients receiving combination anti-retroviral therapy for human immunodeficiency virus (HIV) are excluded from the study
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Pregnancy/nursing status: women who are pregnant should not go on study; women should not breastfeed while participating in this study
- Granulocytes >= 1,500/uL
- Hemoglobin >= 8.5 g/dL; patients with recent or ongoing gastrointestinal bleed may not be transfused to reach the entry hemoglobin of 8.5 g/dL; physicians should ensure patients requiring transfusion prior to registration do not have an occult or clinically apparent gastrointestinal bleed
- Platelets >= 75,000/uL
- Creatinine =< 1.5 x upper limit of normal (ULN) (or creatinine clearance calculated >= 60 cc/minute)
- Child-Pugh score A; patients must meet all laboratory value requirements
- Bilirubin =< 3 mg/dL
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 5 x ULN
- Prothrombin time (PT)-international normalized ratio (INR) =< 1.7 (not required for patients on anticoagulation agents; patients who are being therapeutically anticoagulated with an agent such as Coumadin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01015833

Principal Investigator: | Ghassan Abou-Alfa | Alliance for Clinical Trials in Oncology |
Responsible Party: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT01015833 History of Changes |
Other Study ID Numbers: |
NCI-2011-01989 NCI-2011-01989 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) CDR0000659348 CALGB-80802 ( Other Identifier: Alliance for Clinical Trials in Oncology ) CALGB-80802 ( Other Identifier: CTEP ) U10CA180821 ( U.S. NIH Grant/Contract ) U10CA031946 ( U.S. NIH Grant/Contract ) |
First Posted: | November 18, 2009 Key Record Dates |
Last Update Posted: | August 23, 2017 |
Last Verified: | August 2017 |
Additional relevant MeSH terms:
Liver Neoplasms Carcinoma Carcinoma, Hepatocellular Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Adenocarcinoma Digestive System Neoplasms Neoplasms by Site Digestive System Diseases Liver Diseases Doxorubicin Liposomal doxorubicin Sorafenib |
Niacinamide Antibiotics, Antineoplastic Antineoplastic Agents Topoisomerase II Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Protein Kinase Inhibitors Vitamin B Complex Vitamins Micronutrients Growth Substances Physiological Effects of Drugs |